Innovations in classical hormonal targets for endometriosis

References

• Giudice LC. Endometriosis. N Engl J Med. 2010;362:2389–2398.
   PubMed Web of Science ®Google Scholar
• Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–279.
   PubMed Web of Science ®Google Scholar
• Lazzeri L, Vannuccini S, Orlandini C, et al. Surgical treatment affects perceived stress differently in women with endometriosis: correlation with severity of pain. Fertil Steril. 2015;103(2):433–438.
   PubMed Web of Science ®Google Scholar
• Simoens S, Hummelshoj L, D’Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007;13:395–404.
   PubMed Web of Science ®Google Scholar
• Rogers PA, D’Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16:335–346.
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101(4):927–935.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Crosignani P, Somigliana E, et al. Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod. 2011;26(1):3–13.
   PubMed Web of Science ®Google Scholar
• Streuli I, De Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013;14(3):291–305.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275.
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83(1–5):149–155.
   PubMed Web of Science ®Google Scholar
• Brandenberger AW, Lebovic DI, Tee MK, et al. Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod. 1999;5:651–655.
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Murakami T, Uehara S, et al. Expression of estrogen receptor alpha and beta in peritoneal and ovarian endometriosis. Fertil Steril. 2001;75:1198–1205.
   PubMed Web of Science ®Google Scholar
• Xue Q, Lin Z, Cheng Y-H, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007;77:681–687.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Monsivais D, Kakinuma T, et al. Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin Reprod Med. 2015;33(3):220–224.
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Arterburn JB, Sklar LA. GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol. 2007;265-266:138–142.
   PubMed Web of Science ®Google Scholar
• Imesch P, Samartzis EP, Dedes KJ, et al. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil Steril. 2013;100:770–776.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-β in endometriosis. Semin Reprod Med. 2012;30(1):39–45.
   PubMed Web of Science ®Google Scholar
• Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519.
   PubMed Web of Science ®Google Scholar
• Attia GR, Zeitoun K, Edwards D, et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85:2897–2902.
   PubMed Web of Science ®Google Scholar
• Wu Y, Strawn E, Basir Z, et al. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics. 2006;1:106–111.
   PubMed Web of Science ®Google Scholar
• Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–3826.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130–162.
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh M, Lam EW, Brosens JJ. Mechanisms of endometrial progesterone resistance. Mol Cell Endocrinol. 2012;358:208–215.
   PubMed Web of Science ®Google Scholar
• Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum. Reprod. Update. 2013;19:406–418.
   PubMed Web of Science ®Google Scholar
• Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363–371.
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–1351.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Sept 15]. Available at https://clinicaltrials.gov/ct2/show/NCT01620528?term=endometriosis&rank=26
   Google Scholar
• Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–174.
   PubMed Web of Science ®Google Scholar
• Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertility and Sterility. 2005;84(2):300–304.
   PubMed Web of Science ®Google Scholar
• Pavone ME, Bulun SE Aromatase inhibitors for the treatment of endometriosis [ Review]. Fertil Steril. 2012;98(6):1370–1379. DOI:10.1016/j.fertnstert.2012.08.053. Epub2012 Sep 19.
   PubMed Web of Science ®Google Scholar
• Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. Bjog. 2008;115(7):818–822.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.
   PubMed Web of Science ®Google Scholar
• Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health. 2014;6:671–680.
   PubMedGoogle Scholar
• [cited 2015 Sept 15]. Available at https://clinicaltrials.gov/ct2/show/NCT01190475.
   Google Scholar
• Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012;21(7):905–919.
   PubMed Web of Science ®Google Scholar
• Dunselman GA, Vermeulen N, Becker C, et al., European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau M, Waellnitz K, Nave R, et al. Pharmacokinetic, pharmacodynamic and safety profile o fan intravaginal ring releasing anastrozole and levonorgestrel in healty women. Abstract presented at SEUD congress 2015
   Google Scholar
• Delvoux B, D’Hooghe T, Kyama C, et al. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. J Clin Endocrinol Metab. 2014;99(1):276–284.
   PubMed Web of Science ®Google Scholar
• Kulak J Jr, Fischer C, Komm B, et al. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011;152(8):3226–3232. DOI:10.1210/en.2010-1010. Epub2011 May 17.
   PubMed Web of Science ®Google Scholar
• Naqvi H, Sakr S, Presti T, et al. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biol Reprod. 2014;90(6):121. DOI:10.1095/biolreprod.113.114165.
   PubMed Web of Science ®Google Scholar
• Saito T1, Yoshizawa M, Yamauchi Y, et al. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung. 2003;53(7):507–514.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gong P, Chen Y, et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci Transl Med. 2015;7(271):271.
   Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M, et al. Selective progesterone receptor modulators: an update. Expert Opin Pharmacother. 2014;15(10):1403–1415.
   PubMed Web of Science ®Google Scholar
• Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82(5):442–452.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol. 1998;178(6):1151–1156.
   PubMed Web of Science ®Google Scholar
• Mei L, Bao J, Tang L, et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci. 2010;39(5):421–427.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, DeManno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26:423–438.
   PubMed Web of Science ®Google Scholar
• Klijn JG, Setyono Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000;65(10–11):825–830.
   PubMed Web of Science ®Google Scholar
• Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol. 2009;22(3):450–459.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Sept 15]. Available at https://clinicaltrials.gov/ct2/show/record/NCT00958412?term=proellex&rank=19
   Google Scholar
• Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98299) and ZK 136799 on surgically induced endometriosis in intact rats. Hum Reprod. 1995;10:3264–3271.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Sept 15]. Available at https://clinicaltrials.gov/ct2/show/NCT02213081?term=ulipristal+and+endometriosis&rank=1
   Google Scholar
• Wagenfeld A, Moeller C, Zollner TM. Efficacy of Vilaprisan in an Endometriosis Model and Comparison of Its PR Antagonistic Activity With Other SPRMs in Different Animal Models. Presented as poster at the Society for Reproductive Investigation’s Congress; San Francisco, CA, 2015 Mar 26.
   Google Scholar
• Izawa M, Taniguchi F, Terakawa N, et al. Epigenetic aberration of gene expression in endometriosis. Front Biosci (Elite Ed). 2013;5:900–910.
   PubMedGoogle Scholar
• Attar E, Tokunaga H, Imir G, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab. 2009;94(2):623–631.
   PubMed Web of Science ®Google Scholar
• Han SJ, O’Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014;20(4):467–84).
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov. 2006;5:37–50.
   PubMed Web of Science ®Google Scholar
• Lu Y, Nie J, Liu X, et al. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod. 2010;25:1014–1025.
   PubMed Web of Science ®Google Scholar
• Liu M, Liu X, Zhang Y, et al. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci. 2012;19:360–373.
   PubMed Web of Science ®Google Scholar
• Wu Y, Starzinski-Powitz A, Guo S-W. Prolonged stimulation with tumor necrosis factor-α induced partial methylation at PR-B promoter in immortalized epithelial-like endometriotic cells. Fertil Steril. 2008;90:234–237.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cai S, Wang J, et al. Valproic acid-induced histone acetylation suppresses CYP19 gene expression and inhibits the growth and survival of endometrial stromal cells. Int J Mol Med. 2015 Sep;36(3):725–732.
   Google Scholar